A hybrid artificial intelligence framework for glaucoma monitoring

青光眼是一种复杂的神经退行性疾病，其导致视网膜神经节细胞变性， 它们的轴突随着老年人构成美国人口增长最快的一部分，青光眼将成为 在未来的几十年里，在美国将更加普遍。由于多种因素的复杂相互作用， 青光眼，需要更好的结构和功能预测其进展。的主要障碍 是大量的健康记录数据和复杂的计算模型。我们的总体目标是利用 大数据的力量和快速发展的机器学习方法。NEI的“从大数据到知识” （BD 2K）”倡议和美国眼科学会视力智能研究（IRIS）注册 都是为了利用数据的力量，更好地了解疾病， 预防和治疗。 在这个多PI提案中，我们提供组装超过100万个光学相干断层扫描（OCT）， 青光眼研究网络（GRN）的视野（VF）。我们建议开发一种混合人工 智能（AI）算法，该算法综合了高斯混合模型期望最大化（GEM）和 使用VF识别青光眼进展及其监测的原型机器学习方法， 视网膜神经纤维层（RNFL）厚度测量。我们将把这些工具公开提供给 视觉和眼科研究社区。 我们提出的研究可以提供青光眼预后的实质性改善， 潜在地提供了用于青光眼临床试验的OCT和联合VF/OCT替代终点。

Glaucoma is a complex neurodegenerative disease that results in degeneration of retinal ganglion cells and their axons. With older people making up the fastest growing part of the US population, glaucoma will become even more prevalent in the US in the coming decades. Due to the complex interaction of multiple factors in glaucoma, better structural and functional predictors are needed for its progression. The main impediments are massive health record data and sophisticated computational models. Our overall goal is to leverage the power of big data and rapidly evolving machine learning approaches. The NEI's “Big Data to Knowledge (BD2K)” initiative and the American Academy of Ophthalmology Intelligent Research in Sight (IRIS) registry are all efforts to exploit the power of data and to better understand diseases and to provide improved prevention and treatment. In this multi-PI proposal, we offer to assemble over 1 million optical coherence tomography (OCT) and visual fields (VFs) from the glaucoma research network (GRN). We propose to develop a hybrid artificial intelligence (AI) algorithm that synthesizes Gaussian mixture model expectation maximization (GEM) and archetypal machine learning approach to identify glaucoma progression and its monitoring using VFs and retinal nerve fiber layer (RNFL) thickness measurements. We will make these tools openly available to the vision and ophthalmology research communities. Our proposed studies could offer substantial improvements in the prognosis of glaucoma as well as potentially providing OCT and joint VF/OCT surrogate endpoints to be used in glaucoma clinical trials.